Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dipna Pharmachem submitted its half-yearly financial results for H1 FY26 (ended Sept 30, 2025) along with deviation statements for its earlier Rights Issue and a recent Preferential Issue of convertible warrants. Net sales declined about 20% to Rs. 7,232.83 lakhs from Rs. 9,062.38 lakhs in H1 FY25, yet net profit jumped sharply to Rs. 141.10 lakhs (from Rs. 33.67 lakhs) and EPS rose to Rs. 0.59 from Rs. 0.14, driven by lower purchase costs and reduced inventory build-up. Total equity strengthened to Rs. 5,888.59 lakhs, supported by Rs. 1,898.21 lakhs in share warrant money from the preferential allotment. The company confirmed there is no deviation or variation in the use of proceeds from either the March 2024 Rights Issue or the September 2025 Preferential Issue of convertible warrants, and reported no defaults on loans or debt securities. Related party transactions during the period include commission expenses to the Managing Director (Keyur Shah) of Rs. 669.18 lakhs and to related entities Dhara Chemicals and CEDAC Medicorp.
Despite a top-line decline, the sharp jump in net profit signals improved margins and cost control, which may be viewed positively. The Rs. 18.93 crore raised via convertible warrants strengthens the balance sheet for working capital needs, though the ongoing related party commissions and sales to group entities remain a point to watch for minority shareholders.